Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Pittsburgh
AstraZeneca
University Health Network, Toronto
St. Olavs Hospital
MediLink Therapeutics (Suzhou) Co., Ltd.
University of California, San Diego
Karyopharm Therapeutics Inc
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Akeso
Columbia University
Instituto Nacional de Cancer, Brazil
BeiGene
Shanghai Jiao Tong University School of Medicine
National Cancer Institute, Naples
Cantonal Hospital of St. Gallen
pharmaand GmbH
Guangzhou Gloria Biosciences Co., Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ruhr University of Bochum
Ruhr University of Bochum
Danish Head and Neck Cancer Group
China Medical University Hospital
Royal Marsden NHS Foundation Trust
Daiichi Sankyo
Yonsei University
Amgen
Amgen
Daiichi Sankyo
The University of Hong Kong
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Rigshospitalet, Denmark
Japan Clinical Oncology Group
The First Affiliated Hospital with Nanjing Medical University
M.D. Anderson Cancer Center
Shenzhen SiBiono GeneTech Co.,Ltd
UNICANCER
Seoul National University Hospital
Stanford University
Merck KGaA, Darmstadt, Germany
Sun Yat-sen University
National Cancer Institute (NCI)
Assistance Publique - Hôpitaux de Paris
University of Arkansas
Shanghai Jiao Tong University School of Medicine
Gachon University Gil Medical Center